Bioscience Forum Mining the Microbiome for New Therapeutic Candidates for Chronic Diseases-2017-11-15

Event Information
Event Name: 
Bioscience Forum Mining the Microbiome for New Therapeutic Candidates for Chronic Diseases
Event Date: 
11/15/2017 - 6:00pm
Event Location: 
The Holiday Inn, 275 S Airport Blvd, South San Francisco, California 94080
Event Details
Event Type: 
Event Details: 

Bioscience Forum, Wednesday Evening, Nov. 15, 2017

Topic: "Mining the Microbiome for New Therapeutic Candidates for Chronic Diseases"
Speaker: Karim Dabbagh, Ph.D., Chief Scientific Officer, Second Genome
Date and Time: Wednesday, November 15, 2017 6:00 PM - 9:00 PM
6 pm - 7 pm networking
7 pm - 8 pm dinner
8 pm - 9 pm presentation
Location: The Holiday Inn, 275 S Airport Blvd, South San Francisco, California 94080
Register Here

Event Registration ($3 service fee will apply)
On-Site Registration

Pre-Registration ends Monday, November 13th, at 9 pm
Cash or check accepted on the day of the event
$10 discount for full-time students
Register on organization’s website

Or you can pay with a check made out to "BioScience Forum" and sent to:
BioScience Forum
1442A Walnut Street, #308
Berkeley, CA 94709-1405
Please do not mail checks later than Thursday, November 9th
If paying with check, do not complete online registration with Cvent

Topic Description
The microbiota interacts with itself and its human host to impact health and disease. Inflammatory Bowel Disease (IBD) is a chronic and debilitating condition that results from severe inflammation of the gastrointestinal tract. Two conditions, ulcerative colitis and Crohn's disease, account for the vast majority of the 5 million IBD cases worldwide.

A growing body of scientific evidence suggests a causal link between the gut microbiome and IBD. Theories implicating the microbiome in the pathogenesis of IBD range from activation of the inflammasome through opportunistic pathogens that take advantage of barrier dysfunction, to genetic defects within the host that trigger a deleterious response to normally commensal microbiota. The microbiome is central to the development of chronic intestinal inflammation and subsequent IBD.

Second Genome is actively investigating microbially-mediated mechanisms underlying IBD. By identifying the bacteria that play a key role in IBD, scientific studies have led to identification of new therapeutic approaches and strategies for treating this debilitating condition. A lead candidate is under development that is a small molecule inhibitor of a key microbiome-mediated target to address inflammation and pain in IBD. Furthermore, proteins derived from important bacteria that are reduced in disease settings provide signals that maintain a healthy gut barrier that can be used as novel therapeutics for the treatment of IBD. Finally, the use of this approach and platform in metabolic diseases to identify bacteria and proteins that provide metabolic homeostasis in obesity and diabetes will also be discussed.

Speaker Biography
Karim Dabbagh leads the R&D organization at Second Genome. Prior to that, he led the immunoregulation department at Pfizer, an R&D group focused on innovative approaches to elicit homeostatic immune responses, including microbiome research, for the treatment of immune related disorders. At Pfizer, he also led external R&D innovation for autoimmune and inflammatory diseases. Past responsibilities include founding Modus BioMedicine, a start-up biotechnology company focused on treatments for transplantation and autoimmune disease, as well as spending nine years at Roche Pharmaceuticals in Inflammation Discovery Research.

Dr. Dabbagh received his PhD in biochemistry from University College, London and his BS in biotechnology from the Imperial College of Science, Technology, and Medicine in London. He completed postdoctoral fellowships at the Cardiovascular Research Institute at the University of California, San Francisco and at Stanford University where he worked on elucidating the role played by the microbiome in the hygiene hypothesis.